A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

NCT00309686 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Affective Psychosis, Bipolar
Bipolar Disorder
Mania

Interventions

DRUG: Paliperidone ER

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.